Population pharmacokinetics and dosing simulations of amoxicillin/clavulanic acid in critically ill patients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 11, 2013, Pages 2600-2608

  Carlier, Mieke ^a,b   Noë, Michaël ^a,b   De Waele, Jan J ^b   Stove, Veronique ^b   Verstraete, Alain G ^a,b   Lipman, Jeffrey ^c,d   Roberts, Jason A ^c,d  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

lactams; Amoxicillin; Antibiotics; Clavulanic acid; Critical care medicine; ICU; PK PD

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANIC ACID;

ADULT; AGED; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTENSIVE CARE UNIT; LUNG INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; OPEN STUDY; PROSPECTIVE STUDY; TANDEM MASS SPECTROMETRY;

AMOXICILLIN; ANTIBIOTICS; CLAVULANIC ACID; CRITICAL CARE MEDICINE; ICU; PK/PD; Β-LACTAMS;

ADMINISTRATION, INTRAVENOUS; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CRITICAL ILLNESS; HUMANS; TANDEM MASS SPECTROMETRY;

EID: 84886248419     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt240     Document Type: Article

References (32)

1. Vincent J-L, Rello J, Marshall J et al. International study of the prevalence and outcomes of infection in intensive care units.JAmMedAssoc2009; 302: 2323-9.
2. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.
3. Leibovici L, Shraga I, DruckerM et al. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379-86.
4. Roberts JA, Ulldemolins M, Roberts MS et al. Therapeutic drug monitoring of b-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36: 332-9.
5. Norrby SR. Penicillins and related drugs. In: Grayson LM, ed. Kucers' The Use of Antibiotics. London: Edward Arnold, 2010; 5-256.
6. Turnidge JD. Thepharmacodynamics ofb-lactams. ClinInfectDis1998;27: 10-22.
7. Li C, Du X, Kuti JL et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
8. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
9. Lipman J,Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients:pharmacokinetic modelingindicatesimprovedtroughswith revised dosing. Antimicrob Agents Chemother 1999; 43: 2559-61.
10. Conil JM, Georges B, Lavit M et al. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation. Br J Clin Pharmacol 2007; 64: 27-35.
11. Nicasio AM, Ariano RE, Zelenitsky SA et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53: 1476-81.
12. Roberts JA, Kirkpatrick CMJ,RobertsMSet al. First-doseandsteady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35: 156-63.
13. Roos JF, Lipman J, Kirkpatrick CMJ. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intens Care Med 2007; 33: 781-8.
14. Crandon JL, Ariano RE, Zelenitsky SA et al. Optimization of meropenem dosage in the critically ill population based on renal function. Intens Care Med 2011; 37: 632-8.
15. DohK,WooH, Hur J et al. Populationpharmacokinetics ofmeropenemin burn patients. J Antimicrob Chemother 2010; 65: 2428-35.
16. Lee LS, Kinzig-Schippers M, Nafziger AN et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010; 68: 251-8.
17. Roberts JA, Kirkpatrick CM, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011; 66: 227-31.
18. Ulldemolins M, Roberts JA, Wallis SC et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65: 1771-8.
19. Carlier M, Stove V, Roberts JA et al. Quantification of seven b-lactam antibiotics and two b-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 2012; 40: 416-22.
20. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999; 59: 19-29.
21. Roberts J, De Waele J, Dimopoulos G et al. DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis 2012; 12: 152.
22. Arancibia A, Guttmann J, Gonzalez G et al. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother 1980; 17: 199-202.
23. Sjovall J, Alvan G, Huitfeldt B. Intraindividual and interindividual variation in pharmacokinetics of intravenously infused amoxicillin and ampicillin to elderly volunteers. Brit J Clin Pharmacol 1986; 21: 171-81.
24. Sjovall J, Alvan G, Westerlund D. Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther 1985; 38: 241-50.
25. EUCAST. Antimicrobial Wild Type Distributions of Microorganisms. http://mic.eucast.org/Eucast2/SearchController/search.jsp?action=init (14 May 2013, date last accessed).
26. Grootaert V, Willems L, Debaveye Y et al. Augmented renal clearance in the critically ill: how to assess kidney function. Ann Pharmacother 2012; 46: 952-9.
27. Baptista JP, Udy AA, Sousa E et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011; 15: R139.
28. Martin JH, Fay MF, Udy A et al. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. InternMed J 2010; 41: 537-43.
29. Arlicot N, Marie A, Cade C et al. Stability of amoxicillin in portable pumps is drug concentration dependent. Pharmazie 2011; 66: 631-2.
30. Roberts JA, Kirkpatrick CMJ, Roberts MS et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
31. Roberts JA, Roberts MS, Robertson TA et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
32. Stein GE, Kulhanek G, Smith CL et al. Pharmacokinetics and Monte Carlo simulations of doripenem in patients with febrile neutropenia. Ann Pharmacother 2012; 46: 1281-6.